Trisenox, Ascorbic Acid and Bortezomib in Patients With Relapsed/Refractory Multiple Myeloma

NCT00590603 · clinicaltrials.gov ↗

PHASE1

Phase

TERMINATED

Status

25

Enrollment

OTHER

Sponsor class

Stopped Poor accrual - terminated during Phase I; Phase II never started.

Conditions

Multiple Myeloma

Interventions

DRUG: Arsenic Trioxide, Ascorbic Acid and Bortezomib

Sponsor

Duke University

Collaborators

[object Object]